Veradigm (MDRX) Q2 2025 earnings summary

Executive summary

• New CEO Donald Trigg appointed on September 2, 2025, with a focus on profitability, growth, and SEC filing compliance.

• Commercial team closed over $30 million in annual contract value in Q2 2025, matching Q1 2025 performance.

Financial highlights

• Q2 2025 GAAP revenue estimated between $145 million and $148 million, down 2% year-over-year.

• Cash and equivalents at June 30, 2025, were approximately $350 million, up from $272 million at March 31, 2025.

• Debt at June 30, 2025, was approximately $283 million, including $208 million in convertible notes and $75 million in a term loan facility.

• Provider segment Q2 2025 revenue was $115 million, down from $119 million in Q2 2024; Payer & Life Science segment Q2 2025 revenue was $30 million, up from $29 million in Q2 2024.

Outlook and guidance

• Fiscal year 2025 GAAP revenue expected to be flat compared to 2024's estimated $583–$588 million.

• Net cash is expected to remain positive for the year.